Get started
Royalty Pharma plc 5.2% 25-SEP-2035Royalty Pharma plc 5.2% 25-SEP-2035Royalty Pharma plc 5.2% 25-SEP-2035

Royalty Pharma plc 5.2% 25-SEP-2035

OverviewAnalysisNews

Chart


Full chart

Key terms


Outstanding amount
‪900.00 M‬ USD
Face value
1,000.00 USD
Minimum denomination
2,000.00 USD
Coupon
5.20% (Fixed)
Coupon frequency
Semi-annual
Maturity date
Sep 25, 2035
Term to maturity
9 years

About Royalty Pharma plc 5.2% 25-SEP-2035


Issuer
Royalty Pharma Plc
Sector
Finance
Industry
Financial Conglomerates
Home page
royaltypharma.com
Issue date
Sep 16, 2025
Identifiers
3
ISINUS78081BAU70
Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

See how Royalty Pharma Plc is moving with its highest-yielding bonds.

Analysis


Advanced bond data for paid plans
Unlock important bond data including coupon rates, redemption details, risk assessments, and much more.

News